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ABSTRACT
The pathogenesis of inflammatory bowel disease (IBD) is not yet fully understood. A genetic predisposition,
some environmental factors and microbial flora of the gut are the key factors.
The presence of bacteria in the intestinal lumen is a prerequisite for the development of IBD. In animal
models, mice incapable of expressing IL2 or IL10 invariably develop a colitis- or Crohn-like inflammation. No
inflammation occurs if they grow up in a pathogen-free environment or if they are fed with Lactobacillus sp
when exposed to environmental bacteria. Thus, the absence of luminal bacteria or a different make-up there of
prevents the development of inflammatory bowel disease in this model.
Patients with IBD have been found to have a decreased stool excretion of Lactobacillus and/or Bifidobacteria.
Furthermore, an increased number of bacteria adherents to the mucosa and within the epithelium has been
demonstrated in quantitative studies. It appears that these bacteria trigger a strong abnormal mucosal
immunological response, leading to intestinal epithelial cell injury mediated by activated T-cells, mononuclear
cells and macrophages. If this response can not be down regulated by regulatory T-cells, numerous
inflammatory cytokines are activated by stimulation of the intracellular transcription factor NF-kB. Recently it
was shown that bacterial lipopolysaccharides can activate NF-kB by binding to two specific receptors on the
cell membrane (Toll-like receptors [TLR’s]) or intracellular receptors (NOD’s).
New insights of the role of bacteria in IBD became available by identifying susceptibility genes for IBD.
Several IBD susceptibility loci were recently identified. The IBD-1 locus on chromosome 16 shows positive
evidence for linkage in Crohn’s disease and IBD-2 locus on chromosome 12 for ulcerative colitis. The evidence
for an association with Crohn’s disease at the IBD-1 locus have been shown to be attributed to mutations in the
CARD15/NOD2 gene. This gene is expressed in peripheral blood monocytes and in intestinal epithelial cells
and serves as a key factor of innate mucosal response to luminal bacteria as an antibacterial factor.
The intact intercellular NOD2 protein binds LPS and activates NF-kB. This activation of the NF-kB
signalling pathway in response to bacterial components plays a protective role in the mucosal epithelial cells
for the host against inviting pathogens and an increased apoptosis of infected cells. There is evidence, that the
defective NOD2 protein variants increase the susceptibility to pathogen invasion and a decrease in cellular
apoptosis.
NF-kB plays a dual role in IBD. On the mucosal epithelial cells, bacterial components bind on NOD2
proteins and protect bacterial invasion. If this barrier mechanism is not intact, the bacterial invasion stimulates
via TLR- and NOD2 receptors in immune-active cells (macrophages, T-cells and monocytes) NF-kB and
triggers an aberrant inflammatory response leading to tissue damage.
These new insights in the pathogenesis in IBD have led to new treatment possibilities including pre- and
probiotics. These therapies are aimed at directly modulating the host immune system to suppress intestinal
inflammation. This has prompted considerable interest in manipulating the enteric microenvironment as a novel
therapeutic strategy. Several clinical studies showed promising results using pre- and probiotics in patients with
ulcerative colitis, pouchitis and Crohn’s disease. The introduction of genetically engineered probiotic organism
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to produce and deliver anti-inflammatory cytokines or other biological relevant molecules to the mucosa offers
further new potential for the treatment of IBD.
Keywords : Inflammatory Bowel Disease, inflammatory cytokines
INTRODUCTION
Inflammatory bowel disease (IBD) includes three
clinical conditions: ulcerative colitis (UC), Crohn’s
disease (CD) and indeterminate colitis (IC).
Specific susceptibility genes, triggering
environmental (endogenous or exogenous) factors
together with the intestinal flora are involved in an
aberrant or up-regulated chronic immunological response,
followed by inflammation of intestinal tissue.
There is expanding evidence that intestinal
microorganisms may be directly involved as triggering
factors.1. The crosstalk between intestinal bacteria and
the epithelium and immunological active cells is a field
of considerable scientific interest. Clinical studies have
shown that treatment with pre- and probiotics have an
effect on the clinical outcome in UC, CD and pouchitis.
THE ROLE OF LUMINAL BACTERIA IN IBD
Intestinal epithelial cells (IEC) are constantly exposed
to bacteria and bacterial components. IEC are
structural and functional barriers and serve as a
frontline of host defence against microorganisms. There
is growing evidence, that luminal microorganisms are
involved in the development of IBD.
IL2 gene-deficient knockout mice develop a UC-like
inflammation and IL10 gene-deficient mice a CD-like
inflammation if they are raised under normal conditions.
However, if they are raised under pathogen free
conditions, no inflammatory bowel disease develops.2, 3
In the IL10 deficient mouse model which develop an
inflammation a decreased level of Lactobacillus sp., and
an increased number of bacteria adherent to or
translocated into the colonic mucosa have been found.
However, if these animals were raised with a
supplementation of Lactobacillus plantarum, a reduction
of both adherent and translocated bacteria was found,
and inflammatory condition was prevented.4
In patients with acute UC, the number Lactobacillus
sp. was reduced in the mucosa, as shown in quantitative
analyses of biopsies. In patients with CD a reduction of
Bifidobacteria in stool was found as compared to
non-CD controls. There was no difference if the
patients were in remission.5, 6 Recently, a number of
studies have shown increased numbers of mucosal
adherent and as well intraepithelial bacteria in patients
with IBD, but not in controls.7-10 The concentrations of
mucosal bacteria increased progressively with the
severity of disease, both in inflamed and non-inflamed
colon. In patients with acute IBD multiple polymorphic
bacteria within solitary enterocytes located next to the
lamina propria have been shown. Compared to controls,
the number of anaerobes (e.g. Bacteroides) were
significantly higher.7
These data suggest that bacteria internalized by or
penetrated into enterocytes are important. This may
cause an aberrant mucosal immunoregulation, leading to
intestinal epithelial cell injury mediated by activated
T-cells, mononuclear cells and macrophages.
GENETICS IN IBD
IBD appears to be a complex genetic disorder, with
multiple contributing genes. The IBD-1 linkage region
on chromosome 16q contains the CD susceptibility gene
CARD15/NOD2.11 This gene is expressed in several
cells (peripheral blood monocytes and mucosal epithelial
cells) and serves as a key factor of innate mucosal
response to luminal bacteria. The C-terminus
leucine-rich repeat domain of CARD15/NOD2 serves
as a pattern-recognition receptor for broad types of
microbial components, such as bacterial
lipopolysaccharides (LPS) and peptidoglycan (PDG).12
The NOD2 protein serves as an intracellular receptor
for LPS and PDG and this is followed by activation of
the intracellular transcription factor NF-kB.
With one copy of the risk alleles, the risk to develop
CD is about 2-4 fold increased; with double-dose
carriage the risk increases 20-40 folds (13). If the NOD2
mutation is present, a decreased NF-kB activation in
response to bacterial components was observed.14 The
innate host reaction to enteric bacteria is impaired. Thus,
the greater exposure to such bacteria can trigger an
aberrant T-cell inflammatory response.15
The IBD-2 linkage region on chromosome 12q was
found more often in UC.16
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Present research is aimed to elucidate, how such a
genetically determined dysregulation of the host immune
response against bacteria leads to development of   clinical
IBD.
IMMUNE RESPONSE IN IBD
It is suggested that the intracellular transcription
factor NF-kB plays a dual role in IBD. On the mucosal
epithelial cells, bacterial components bind to NOD2
proteins and protect bacterial invasion. If this barrier is
disrupted, the invading bacteria stimulate via toll-like
receptors (TLR’s) and NOD2 receptors of
macrophages, T-cells and monocytes the expression of
NF-kB and trigger thereby an aberrant inflammatory
response leading to tissue damage.
In CD, high levels of activated NF-kB can be found
in the inflamed intestinal mucosa.17  Bacterial products
signalling TLR’s may activate NF-kB. TLR4 is abun-
dantly expressed by mononuclear cells in the epithelium
and lamina propria in patients with IBD.18 TLR4 serves
as major transducing subunit of the LPS receptor
complex. It is conceivable that increased LPS
recognition and signalling may contribute to the enhanced
NF-kB activity and subsequent synthesis of
inflammatory cytokines in IBD (Fig.1).
Several genes are regulated by NF-kB and their
products TNFα, IL1, IL6, IL8 and IFNγ or intracellular
adhesion molecule are important mediators in
inflammation. Furthermore, TNFα up regulates the
NOD2 protein in epithelial cells. TNFα can activate
resistant macrophages, promote the release of other
proinflammatory mediators and induce expression of
adhesion molecules to the vascular endothelium,
facilitating the migration of new inflammatory cells into
the mucosa. TNFα can also contribute to the intestinal
damage by directly altering the integrity of epithelial
membranes. It was also shown that IECs over
expressing NOD2 are sensitized to LPS and secrete high
levels of chemotactic cytokine IL8 on LPS stimulation.
Thus, regulation of NOD2 expression could be an
important part of the innate immune response in
intestinal epithelial cells. Defective NOD2 protein
variants genetically associated with Crohn’s disease may
further enhance inflammatory processes by perturbing
epithelial barrier functions (Fig. 2).
If this impaired function persists, an uncontrolled Th1
cell activation by intracellular bacteria through the
release of IL12 from macrophages is present with the
release of pro-inflammatory cytokines (IL2, IFNγ). On
the other hand, the anti-inflammatory Th 2 cytokine
response (IL4, IL10, and TGFβ) is decreased. IFNγ can
facilitate the activation of resistant macrophages and the
release of IL1, IL6 and TNFα which maintain or increase
the local inflammatory response. The differentiation of
Th 2 cytokine producing cells (IL4, IL5, and IL13) is
inhibited by IFNγ. It is also known that the IL10 down
regulation of activated Th1 cells is also impaired (Fig.3).
It is important to recognize, that the mucosal immune
response is different in UC and CD. There are
differences in the expression of cytokines between the
two diseases. In CD a Th 1 response is dominant with
an increased expression of INFγ, IL2, IL12 and IL18.19
This is followed by an increase of the proinflammatory
cytokines TNFα, IL1β and NF-kB.
In UC a Th 2 response with a decreased Th 1
response is more dominant. The Th 2 response increases
the expression of IL4, 5, 6 and IL10.
The factor/mechanisms leading to this uncontrolled
T-cell activation are not fully clarified. The loss of
tolerance towards the resident bacterial flora appears to
be important, and it is believed that counter-regulatory
molecules (TGFβ, IL10) involved in maintaining tolerance
towards the resistant flora may play a role in regulating
mucosal T-cell activation. It was recently shown that
TGFβ1 activity is defective in IBD mucosa because of
enhanced production of Smad7, an inhibitor of TGFβ1
signal transduction.20 Furthermore, it was demonstrated,
that CD mucosal T-cells display a defective apoptosis to
several stimuli, associated with an increased ratio
between the antiapoptotic protein Bcl-2 and the
proapoptotic molecule Bax.21
This knowledge is the background to interfere in the
microbial-host interaction with pre- and probiotics either
to prevent or to treat IBD.
NEW TREATMENT OPTION FOR IBD
The role of the intestinal flora and the interaction with
the intestinal immune system leading to an uncontrolled
immune response in genetic susceptible patients has lead
to an interest to use pre- and probiotics in patients with
IBD.
There is a growing body of knowledge how pre- and
probiotics interfere with the balance of pathogenic and
apathogenic bacteria.
PREBIOTICS IN IBD
The most widely used prebiotics are soluble fibre
which can be fermented in the colon to short chain fatty
acids (SCFA); thereby stimulating the growth of
beneficial bacteria (e.g. Bifidobacteria, Lactobacilli)
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inhibiting the growth of harmful bacteria
(e.g. Bacteroides, Clostridium difficile, E. coli).22 SCFA’s
are the main energy source for colonocytes. Insufficient
colonic amounts of butyrate and/or impaired oxidation
by colonocytes are involved in the pathogenesis of UC.23-
26
 Excessive intraluminal hydrogen sulphide by increased
amounts of sulphate-reducing bacteria is proposed to
impair butyrate oxidation in UC.27 Furthermore, butyrate
itself has anti-inflammatory properties by inhibiting
NF-kB. It was shown in an elegant experiment that
butyrate decreases TNFα and cytokine messenger RNA
expression in colonic epithelial cell lines. It also
diminishes the endotoxin-induced expression of cytokines
by peripheral blood mononuclear cells.28
Several clinical trials, both controlled and uncontrolled
using enemas of SCFA or butyrate have recently
reviewed the beneficial effect of butyrate, either given
directly or produced by fermentable fibre in patients with
UC.24 Higher rates of clinical remission and a
significant reduction in stool frequency have been found
with topical butyrate in combination with mesalazine as
compared to placebo or mesalazine alone.29 In a small
double-blind, randomized controlled trial the effect of an
oral butyrate preparation to be released in the colonic
lumen in combination with mesalazine compared to
mesalazine alone in 25 patients with active UC was
recently published.30 The remission rates were similar in
both groups, although a trend was observed towards a
greater efficacy with butyrate,30 Plantago ovata seeds
(a slowly fermentable fibre) showed a similar one-year
relapse rate compared to standard mesalazine treatment
in patients with quiescent UC in another trial.31
PROBIOTICS AND IBD
Probiotics are living organisms, which when ingested
in certain number, exert health benefits beyond inherent
basic nutrition. Several probiotics (e.g. Lactobacilli, E.
coli Nissle, Saccharomyces boulardii, and VSL-3
(a mixture of three strains of Bifidobacteria, four strains
of Lactobacilli and one strain of Streptococcus
thermophilus) were used in clinical trials.
It is known that probiotics stimulate sIgA secretion
by mucosal adhesion and mucus production. Furthermore,
they can stimulate phagocytosis and reduce TNFα and
IFNγ.
In several experimental colitis models the
administration of probiotics was beneficial either in
reducing inflammation or in prevention of colitis.32-35
Madsen et al. reported that the treatment with VSL-3
brought about significant improvement of inflammation
together with a reduction in mucosal levels of
proinflammatory cytokines (TNFα, INFγ) and
a normalization of colonic physiologic function and
barrier integrity in IL10 knockout mice.35
In humans, several studies in patients with UC were
published using probiotics with promising results.
Figure 1. Bactreria and IBD: Pathogen bacteria enter through M-cells
or directly in the cells. Stimulation of inflammatory cytokines by
Th1-cells or via LPS by macrophages or monocytes through NF-kB.
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Figure 2. Mutated NOD2 impairs epithelial integrity and facilitates the
invasion of bacteria in the mucosal cells, which is followed by
activation of inflammatory cytokines
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A non-pathogenic strain of E. coli (Nissle) has been
reported to have efficacy equivalent to that of mesalazine
in preventing relapse in patients with ulcerative colitis.36-
38
 On the other hand, a study with Lactobacillus GG
compared to placebo was not better in maintaining
postoperative remission rates in CD.39
The most impressive data for the efficacy of probiotics
were published for the maintenance of remission or the
prevention of onset in pouchitis. In the first study, 40
patients with chronic pouchitis who went into remission
after 1 month of antibiotic treatment with ciprofloxacin
plus rifaximin, were randomly selected to receive
VSL-3 (6 g/d) or placebo for 9 months in a double-blind
trial.40 Microbiologic determination showed a notable
increase in the concentration of Lactobacilli,
Bifidobacteria, and Streptococcus termophilus. All 20
patients treated with placebo had a relapse during the
follow-up period. In contrast, 17 of the 20 patients treated
with VSL-3 were still in remission after 9 months. All
these 17 patients had a relapse within 4 months after
suspension of the treatment. Prolonged treatment of
pouchitis with VSL-3 broad a significant increase of
tissue levels of IL10, a significant decrease of tissue   levels
of proinflammatory cytokines (TNFα, INFγ and IL1).
In the second study Gionchetti et al41 compared
VSL-3 with placebo in a double-blind, placebo-controlled
trial (1 year) in the prophylaxis of pouchitis. In the
VSL-3 group (n = 20) only 2 patients had an acute
pouchitis, compared to placebo with 8 of 20 patients.
Future approaches to immunotherapy in
inflammatory bowel disease include genetically
engineered bacteria, which secret immunosuppressive
cytokines, as validated by treatment of experimental colitis
by Lactococcus lactis producing IL10.42
Although the results of these studies are exciting and
intriguing, large, well-designed and well-controlled  studies
of pre- and probiotics are further needed.
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